Valuation: Mylan Inc

Market Cap 19.09B 16.74B 15.51B 14.27B 26.99B 1,827B 27.51B 185B 72.48B 897B 71.67B 70.11B 3,098B P/E 2026 *
70.3x
P/E 2027 * 26x
Enterprise Value 31.27B 27.43B 25.41B 23.38B 44.21B 2,993B 45.07B 303B 119B 1,470B 117B 115B 5,076B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 2x
Free-Float
92.23%
Yield 2026 *
3.1%
Yield 2027 * 3.18%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-1.52%+49.04%+171.88% 1,054B
+0.31%-0.60%+64.29%+62.31% 621B
-0.03%-2.65%+28.86%+85.64% 438B
-0.23%-2.83%+28.02%+21.64% 325B
-0.63%-2.38%+28.36%+45.69% 281B
-0.32%-12.48%+17.91%+21.77% 262B
-1.39%-1.97%-27.58%-39.63% 219B
-0.81%-1.63%+22.07%+58.33% 195B
+1.21%+1.38%+19.85%+71.29% 163B
Average -0.23%-1.70%+25.65%+55.44% 395.13B
Weighted average by Cap. -0.23%-1.69%+35.84%+83.57%

Financials

2026 *2027 *
Net sales 14.77B 12.96B 12B 11.04B 20.89B 1,414B 21.29B 143B 56.1B 694B 55.48B 54.27B 2,398B 15.04B 13.19B 12.22B 11.24B 21.26B 1,439B 21.67B 146B 57.1B 707B 56.47B 55.23B 2,441B
Net income 13M 11.4M 10.56M 9.72M 18.38M 1.24B 18.73M 126M 49.36M 611M 48.81M 47.74M 2.11B 498M 436M 404M 372M 703M 47.62B 717M 4.82B 1.89B 23.39B 1.87B 1.83B 80.76B
Net Debt 12.19B 10.69B 9.9B 9.11B 17.23B 1,166B 17.56B 118B 46.28B 573B 45.76B 44.76B 1,978B 11.03B 9.67B 8.96B 8.24B 15.59B 1,056B 15.9B 107B 41.89B 518B 41.42B 40.52B 1,790B
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-